Evidence for a Secondary State of the Human β3-Adrenoceptor
- 1 December 2005
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 68 (6) , 1645-1655
- https://doi.org/10.1124/mol.105.015461
Abstract
There are three members of the beta-adrenoceptor family, all of which are primarily coupled to G(s) proteins. Recent studies using the huge range of beta-ligands now available have given remarkable new insights into their pharmacology. beta1-adrenoceptors exist in at least two active conformations, whereas beta2-adrenoceptors are able to induce signaling via different agonist-induced receptor conformational states, and their affinity for antagonists can be altered by highly efficacious agonists. This study therefore examined the pharmacology of the human beta3-adrenoceptor stably expressed in Chinese hamster ovary cells. Several compounds described previously as beta-antagonists have agonist properties at the beta3-adrenoceptor. Antagonist affinity measurements varied at the beta3-adrenoceptor in a manner similar to those observed at human beta1-adrenoceptors and unlike those seen at beta2-adrenoceptors. Some ligands (e.g., fenoterol and cimaterol) were more readily inhibited by all antagonists, whereas other ligands [e.g., alprenolol and 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride [SR 59230A]) stimulated responses that were more resistant to antagonism. Alprenolol inhibited fenoterol-induced beta3-adrenoceptor responses while acting as an agonist at higher concentrations. This is highly suggestive of two active conformational states of the beta3-adrenoceptor. (S)-4-[2-Hydroxy-3-phenoxypropylaminoethoxy]-N-(2-methoxyethyl)phenoxyacetamide (ZD 7114) stimulated a two-component response, of which the first component was more readily antagonized than the second. Taken together, these experiments suggest that the human beta3-adrenoceptor exists in at least two different agonist conformations with a similar high- and low-affinity pharmacology analogous to, if not as pronounced as, the beta1-adrenoceptor. Both conformations are present in living cells and can be distinguished by their pharmacological characteristics. In this respect, the human beta3-adrenoceptor seems similar to the human beta1-adrenoceptor.Keywords
This publication has 34 references indexed in Scilit:
- Site of Action of β-Ligands at the Human β1-AdrenoceptorThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Evidence for Pleiotropic Signaling at the Mouse β3-Adrenoceptor Revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2 S-2-propanol Oxalate]The Journal of Pharmacology and Experimental Therapeutics, 2005
- The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptorsBritish Journal of Pharmacology, 2005
- Do low‐affinity states of β‐adrenoceptors have roles in physiology and medicine?British Journal of Pharmacology, 2004
- Influence of Agonist Efficacy and Receptor Phosphorylation on Antagonist Affinity Measurements: Differences between Second Messenger and Reporter Gene ResponsesMolecular Pharmacology, 2003
- Cardiac‐specific overexpression of human β2 adrenoceptors in mice exposes coupling to both Gs and Gi proteinsBritish Journal of Pharmacology, 2003
- Lead poisoning: case studiesBritish Journal of Clinical Pharmacology, 2002
- Mouse β3a‐ and β3b‐adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathwaysBritish Journal of Pharmacology, 2002
- Potential Use of β3‐Adrenoceptor Antagonists in Heart Failure TherapyCardiovascular Drug Reviews, 2002
- Anomalous Behavior of CGP 12177A ON β2-Adrenergic ReceptorsJournal of Receptors and Signal Transduction, 1996